Syed Sameer Nasir, MD | Authors

Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting

August 16, 2016

This article will address changes in CINV guidelines over the past 5 years and provide updates on recently approved agents and agents that are expected to be approved, based on published phase III trials. It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV.

Update on the Management of Primary CNS Lymphoma

February 01, 2000

Primary central nervous system (CNS) lymphoma is a non-Hodgkin’s lymphoma restricted to the nervous system. The incidence of this lymphoma is rising in the immunocompetent population but may be decreasing in patients